Barclays PLC lifted its position in shares of Novavax, Inc. (NASDAQ:NVAX - Free Report) by 73.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 709,579 shares of the biopharmaceutical company's stock after purchasing an additional 301,627 shares during the quarter. Barclays PLC owned approximately 0.44% of Novavax worth $8,961,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Banque Cantonale Vaudoise grew its stake in Novavax by 500.0% in the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 2,500 shares during the period. Amalgamated Bank grew its position in shares of Novavax by 26.9% in the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company's stock valued at $62,000 after purchasing an additional 1,036 shares during the last quarter. Signaturefd LLC grew its position in Novavax by 214.5% during the second quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company's stock worth $72,000 after buying an additional 3,874 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Novavax by 38.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 1,598 shares during the last quarter. Finally, Midland Wealth Advisors LLC bought a new stake in Novavax during the second quarter worth $152,000. Institutional investors own 53.04% of the company's stock.
Novavax Price Performance
Shares of NVAX stock traded down $0.37 during trading hours on Wednesday, reaching $8.63. 3,815,405 shares of the company traded hands, compared to its average volume of 9,254,664. The firm has a 50-day moving average price of $9.37 and a 200 day moving average price of $12.04. Novavax, Inc. has a 12-month low of $3.53 and a 12-month high of $23.86. The company has a market cap of $1.38 billion, a P/E ratio of -3.82 and a beta of 2.02.
Novavax (NASDAQ:NVAX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.07. The business had revenue of $84.51 million for the quarter, compared to analysts' expectations of $65.80 million. During the same quarter in the prior year, the company posted ($1.26) earnings per share. The firm's quarterly revenue was down 54.8% compared to the same quarter last year. Sell-side analysts predict that Novavax, Inc. will post -1.44 EPS for the current year.
Analyst Ratings Changes
Several research analysts recently issued reports on the company. B. Riley reaffirmed a "buy" rating and set a $26.00 target price (up from $23.00) on shares of Novavax in a research report on Thursday, October 10th. HC Wainwright reiterated a "buy" rating and set a $19.00 price target on shares of Novavax in a research note on Tuesday, December 10th. Finally, Jefferies Financial Group dropped their target price on shares of Novavax from $31.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Novavax has a consensus rating of "Hold" and an average target price of $17.83.
Get Our Latest Analysis on NVAX
Novavax Profile
(
Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Further Reading
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
